• Immutep gets patent in Japan
  • Patrys completes engineering run, prepares for Phase 1 trial
  • Bod set to acquire Aqua Phase technology

Immutep (ASX:IMM) has been granted a patent in Japan relating to the combined therapeutic preparations which comprise its lead immunotherapy candidate LAG-3 fusion protein (LAG-3Ig) and an anti-PD-(L)1 antibody.

In addition to these broad claims, the granted patent also covers narrower claims drawn to specific combinations of efti with various approved PD-(L)1 antibodies.

In all, the claims provide comprehensive coverage of both combination products and combination therapies combining efti and and anti-PD-(L)1 antibody.

This new Japanese patent follows the grant of the corresponding Australian, European, US and Chinese patents announced in 2018 through to 2022.

The patent expiry date will be 8 January 2036.

“We are pleased to see continued progress in building our global patent estate around efti,” said Immutep CEO, Marc Voigt.

“This is especially meaningful when coupled with the very promising data we have reported from TACTI-002 in three cancer indications, along with the initiation of TACTI-003 in the past 12 months,” he said.

Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321 ), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer.

Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune diseases.

 

Immutep share price today:

 

 

Patrys prepares for Phase 1 trial

Patrys (ASX:PAB) says its PAT-DX1 engineering run has met all specification tests, which means that PAT-DX1 can now be used to complete the remaining pre-clinical toxicology studies in preparation for a Phase 1 clinical trial.

The testing was a necessary requirement to ensure high-quality pharmaceuticals are used in GMP and clinical studies.

A wide range of analytical tests were conducted to analyse the physical characteristics of the drug substance, and to ensure that the activity and purity of the drug material fall within pre-defined tolerance levels.

It was conducted by a third party Contract Development Manufacturing Organization (CDMO).

Patrys has already successfully completed animal toxicology studies using non-GLP PAT-DX1 drug material, and these showed that it is safe and well-tolerated.

These data have been used to inform the design of GLP toxicology studies for PAT-DX1, which are scheduled to commence in quarter four.

“We are very pleased to have developed and refined a manufacturing process for PAT-DX1 that puts us on a solid trajectory to initiate the planned Phase 1 clinical trial in the second half of 2023,” said CEO Dr James Campbell.

 

 

 

Patrys share price today:

 

 

Bod to acquire Aqua Phase

Cannabis focused drug development company, Bod Australia (ASX:BOD), is set to acquire ‘Aqua Phase’.

Aqua Phase is a process technology to increase the bioavailability of cannabis compounds, together with all intellectual property, confidential information, records, goodwill and the right to use the name ‘Aqua Phase’.

Bod will pay GBP 1 million initially, and will then pay GBP 0.5 million and GBP 1.5 million if two certain milestones were achieved.

These two milestones will be paid by issuing Bod shares.

The company’s shares are currently in a trading halt while the placement component of its capital raising is being undertaken.

The trading halt is expected to end on Thursday.

 

 

BOD Australia share price today:

 

Read MoreBiotech

Featured Companies

You might be interested in